Literature DB >> 4075410

Monoclonal anti-human tumor antibodies of six isotypes in cytotoxic reactions with human and murine effector cells.

D Herlyn, M Herlyn, Z Steplewski, H Koprowski.   

Abstract

Eighty-seven murine monoclonal antibodies (MAb) produced against human tumors of various origins and representing six different immunoglobulin classes were tested for antitumor reactivity in antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) assays. Mouse splenocytes, thioglycolate-elicited mouse peritoneal macrophages, freshly obtained nonadherent human peripheral blood lymphocytes, and human monocytes were used as effector cells, and human or rabbit serum as the source of complement. Of all four effector cell types tested, mouse macrophages showed the highest cytotoxic activity, based on net cytotoxicity, minimum requirement for Mab concentration, and effector cell number. Different immunoglobulin classes were associated with characteristic patterns of reactivity with the various effector cells or complement, independent of the target cell type used. MAb able to mediate ADCC were found among all IgG subclasses, with IgG2a and IgG3 MAb inducing lysis with all effector cell types. IgM and IgA MAb were nonreactive in the various ADCC assays, but IgM MAb were highly cytotoxic with complement.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4075410     DOI: 10.1016/0008-8749(85)90068-1

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  13 in total

1.  Biological activity in the human system of isotype variants of oligosaccharide-Y-specific murine monoclonal antibodies.

Authors:  D Scholz; M Lubeck; H Loibner; J McDonald-Smith; Y Kimoto; H Koprowski; Z Steplewski
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  TM4SF1: a new vascular therapeutic target in cancer.

Authors:  Chi-Iou Lin; Anne Merley; Tracey E Sciuto; Dan Li; Ann M Dvorak; Juan M Melero-Martin; Harold F Dvorak; Shou-Ching S Jaminet
Journal:  Angiogenesis       Date:  2014-07-02       Impact factor: 9.596

3.  In vivo efficacy of monoclonal antibody-drug conjugates of three different subisotypes which bind the human tumor-associated antigen defined by the KS1/4 monoclonal antibody.

Authors:  J J Starling; R S Maciak; N A Hinson; C L Nichols; S L Briggs; B C Laguzza
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  Chimeric B72.3 mouse/human (IgG1) antibody directs the lysis of tumor cells by lymphokine-activated killer cells.

Authors:  F J Primus; T K Pendurthi; P Hutzell; S Kashmiri; D C Slavin; R Callahan; J Schlom
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

5.  Biological characterization of a chimeric mouse-human IgM antibody directed against the 17-1A antigen.

Authors:  W E Fogler; L K Sun; M R Klinger; J Ghrayeb; P E Daddona
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

6.  Differential effects of a murine and chimeric mouse/human anti-interleukin-2 receptor antibody on human T-cell proliferation.

Authors:  B Rose; A Gillespie; D Wunderlich; K Kelley; J Dzuiba; D Shedd; K Cahill; B Zerler
Journal:  Immunology       Date:  1992-07       Impact factor: 7.397

7.  Isolation and characterization of anti-monosialoganglioside monoclonal antibody 19-9 class-switch variants.

Authors:  Z Steplewski; G Spira; M Blaszczyk; M D Lubeck; A Radbruch; H Illges; D Herlyn; K Rajewsky; M Scharff
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

8.  Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity.

Authors:  Z Steplewski; L K Sun; C W Shearman; J Ghrayeb; P Daddona; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

9.  Cytotoxicity of white blood cells activated by granulocyte-colony-stimulating factor, granulocyte/macrophage-colony-stimulating factor and macrophage-colony-stimulating factor against tumor cells in the presence of various monoclonal antibodies.

Authors:  P Ragnhammar; J E Frödin; P P Trotta; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1994-10       Impact factor: 6.968

Review 10.  An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders.

Authors:  Nicholas J Ashton; Abdul Hye; Anto P Rajkumar; Antoine Leuzy; Stuart Snowden; Marc Suárez-Calvet; Thomas K Karikari; Michael Schöll; Renaud La Joie; Gil D Rabinovici; Kina Höglund; Clive Ballard; Tibor Hortobágyi; Per Svenningsson; Kaj Blennow; Henrik Zetterberg; Dag Aarsland
Journal:  Nat Rev Neurol       Date:  2020-04-22       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.